CN103356626B - Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases - Google Patents
Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases Download PDFInfo
- Publication number
- CN103356626B CN103356626B CN201310332524.6A CN201310332524A CN103356626B CN 103356626 B CN103356626 B CN 103356626B CN 201310332524 A CN201310332524 A CN 201310332524A CN 103356626 B CN103356626 B CN 103356626B
- Authority
- CN
- China
- Prior art keywords
- pyrazolopyrimidine compound
- compound
- treatment
- trichophyton rubrum
- infected diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention relates to a use of a pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases. The pyrazolopyrimidine compound is N3-(4-fluoropentyl)-1H-pyrazolo[3,4-D]pyrimidine-3,4-diamine. The pyrazolopyrimidine compound has good activity of resisting various shallow and deep fungi. Compared with the existing antifungal drugs in clinical application, the pyrazolopyrimidine compound has the advantages of high efficiency, low toxicity and wide antifungal spectrum and can be used for preparation of antifungal drugs.
Description
Technical field
The present invention relates to the application of a kind of compound, specifically, is the application about a kind of throat azoles miazines compound.
Background technology
The position that fungal infectious disease invades human body according to fungus is divided into 4 classes: Superficial mycoses, dermatomycosis, subcutaneous mycosis and systemic mycoses; The former two is collectively referred to as superficial mycosis, and the latter two are also called deep mycosis.Fungal infectious disease is divided into following several according to fungal infection difference: candida albicans bacterium infectious disease, Candida parapsilosis bacterium infectious disease, Candida glabrata infectious disease, infection by Cryptococcus neoformans disease, Gypsum Fibrosum shape sporidiole bacteria infectious disease, trichophyton infectious disease, aspergillus fumigatus infection disease.
In recent years, along with the extensive use of broad ectrum antibiotic, corticosteroid and immunosuppressant, advanced Clinics is as the popularization of organ transplantation etc., AIDS's is popular, and the impact of tumor Radiotherapy chemotherapy, cause fungal infection particularly deep fungal infection significantly rise, deep fungal infection has now become the major disease such as acquired immune deficiency syndrome (AIDS) and tumor main causes of death.
The nitrogen azole compounds reported at present and commonly use clinically has ketoconazole (Ketoconazole, KCZ), fluconazol (Fluconazole, FCZ), voriconazole (Voriconazole, VCZ), itraconazole (Itraconazole, ICZ), amphotericin B (Amphotericin B, AMB) etc., the defects such as but these compounds still exist, and above-mentioned toxic and side effects is large, narrow antimicrobial spectrum, easily generation drug resistance, the dosage such as played needed for drug effect is comparatively large, thus can produce larger toxic and side effects to human body.。
Summary of the invention
The object of the invention is for deficiency of the prior art, the application that a kind of throat azoles miazines compound catches trichophyton is provided.
For achieving the above object, the technical scheme that the present invention takes is: the application of a kind of throat azoles miazines compound in preparation trichophyton infectious disease medicament, described throat azoles miazines compound is N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3,4-diamidogen.
The invention has the advantages that: compound of the present invention has good antifungal activity to various superficial part and deep fungal, compared with the antifungal drug of existing clinical practice, to there is the advantages such as efficient, hypotoxicity, anti-fungus spectra are wide, can be used for preparing antifungal drug.
Detailed description of the invention
Below detailed description of the invention provided by the invention is elaborated.
Embodiment 1
Below detailed description of the invention provided by the invention is elaborated.
(1) experimental technique: adopt conventional antibacterial experiment in vitro method (referring to: Antimicrob Agents Chemother 1995,39 (5): 1169)
1. materials and methods
(1) testing compound of the present invention: N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3,4-diamidogen
The experiment of particular compound:
Buy the Tocris Bioscience(U.S., Ellisville) ready-made compound (Cat. No. 2731) carries out cytologic experiment, and specifying information is as follows:
CGP57380，CAS?number：522629-08-9
Molecular weight: 244.23
Chemical name: N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3,4-diamidogen (N3-(4-Fluorophenyl)-1H-pyrazolo-[3,4-d] pyrimidine-3,4-diamine)
Molecular formula: C
11h
9fN
6.
Experimental strain is as follows:
This experiment has selected following 8 kinds of common human body cause illness's standard fungal bacterial strains as screening object:
Table 1 antifungal activity in-vitro screening strain subject
(2) test method
Bacteria suspension is prepared: above-mentioned fungus is cultivated 16 hours through YEPD fluid medium 35 DEG C, twice activation, with blood cell counting plate counting, with RPM1640 fluid medium adjustment bacteria concentration to 1 × 10
4~ 1 × 10
5individual/mL.
Drug solution preparing: get testing compound of the present invention and be dissolved in dimethyl sulfoxine, is made into the medicament storage liquid of 8.0mg/mL, tests front RPM1640 and is diluted to 640 μ g/mL.
Inoculation: get drug sensitive plate, adding RPMI RPMI-1640 200 μ l in often arranging No. 1 hole, making blank; No. 12 holes add bacterium liquid 200 μ l to be measured, make negative control; Drug sensitive plate is often arranged 2 ~ No. 11 holes and is added bacterium liquid 180 μ l respectively, fully mixes, and make the final drug level in each hole be respectively 64,32,16,8,4,2,1,0.5,0.25 and 0.125 μ g/ml, in each hole, DMSO content is all lower than 1%; No. 12 hole not drug containing, make positive control.Control drug is fluconazol (FCZ), itraconazole (ICZ), voriconazole (VCZ), ketoconazole (KCZ), terbinafine (TBR), amphotericin B (AMB).
Cultivate and detect: set Positive control wells optical density value (OD value) as 100%, with optical density value than Positive control wells lower than 80% lowest concentration of drug for minimal inhibitory concentration value (MIC
80).
(2) experimental result
Antibacterial experiment in vitro the results are shown in Table 2.
Table 2 the compounds of this invention is to common causative fungus external activity (MIC, μ g/ml)
Note: KCZ. ketoconazole, FCZ. fluconazol, VCZ. Wo Likang azoles, ICZ. itraconazole, TRB. terbinafine, AMB amphotericin
Above-mentioned experimental result shows that compound of the present invention has good antifungal activity, and the vitro inhibition activity of compound to selected fungus is all far better than fluconazol, illustrates that the compounds of this invention can be used for preparing the medicine of anti-fungal infection.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the prerequisite not departing from the inventive method; can also make some improvement and supplement, these improve and supplement and also should be considered as protection scope of the present invention.
Claims (1)
1. the application of Pyrazolopyrimidines in the medicine of preparation treatment trichophyton infectious disease, described Pyrazolopyrimidines is N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3,4-diamidogen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310332524.6A CN103356626B (en) | 2013-08-02 | 2013-08-02 | Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310332524.6A CN103356626B (en) | 2013-08-02 | 2013-08-02 | Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103356626A CN103356626A (en) | 2013-10-23 |
| CN103356626B true CN103356626B (en) | 2015-01-07 |
Family
ID=49359443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310332524.6A Expired - Fee Related CN103356626B (en) | 2013-08-02 | 2013-08-02 | Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356626B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY33241A (en) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ? Tienopyrimidines containing heterocycloalkyl for pharmaceutical compositions ?. |
-
2013
- 2013-08-02 CN CN201310332524.6A patent/CN103356626B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103356626A (en) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2368078T3 (en) | PHARMACEUTICAL COMPOSITION AND METHOD USED BY AN ANTIFUNGICAL AGENT IN COMBINATION. | |
| US20230364067A1 (en) | Antifungal agents with enhanced activity in acidic ph | |
| CN110769854B (en) | Antifungal agents for use in combination | |
| US20150366845A1 (en) | Pharmaceutical composition for diseases caused by pathogenic microorganisms such as aspergillus | |
| Bormann et al. | Review of the pharmacology and clinical studies of micafungin | |
| CN103275024B (en) | Azole antifungal compound and its preparation method and application | |
| CN103356626B (en) | Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases | |
| CN103417545B (en) | Application of pyrazolopyrimidine compound in preparing medicines for aspergillus fumigatus infectious diseases | |
| CN103356624B (en) | Use of pyrimidine compound in antifungal drugs | |
| Khan et al. | Antifungal potential of disulfiram | |
| CN103405439B (en) | Application of pyrimidine compound to preparing antifungal medicines | |
| CN103356627B (en) | Use of drug in treatment on candida glabrata infected diseases | |
| CN103356628B (en) | Use of pyrazolopyrimidine compound in pharmacy | |
| CN103356625B (en) | Use of pyrazolopyrimidine compound in treatment on candida parapsilosis infected diseases | |
| Werbel et al. | Angioinvasive, cutaneous infection due to Colletotrichum siamense in a stem cell transplant recipient: Report and review of prior cases | |
| CN103585143A (en) | Application of formononetin in preparation of aspergillus fumigatus resistant medicament | |
| CN103565794A (en) | Application of 7-hydroxy-4'-methoxyisoflavone in antifungal medicament | |
| RU2497521C1 (en) | Pharmaceutical composition possessing antifungal activity, and method for preparing it | |
| CN103565791A (en) | Application of formononetin in trichophyton rubrum | |
| CN103565793A (en) | Application of formononetin in antifungal medicaments | |
| CN103565795A (en) | Application of formononetin in antifungal medicaments | |
| CN103565790A (en) | Application of formononetin in cryptococcus neoformans | |
| CN103565792A (en) | Application of formononetin in microsporum gypseum | |
| Wafer et al. | Trichophyton tonsurans associated tinea corporis infection with the development of Majocchi's granuloma in a renal transplant patient | |
| An et al. | Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI TENTH PEOPLE'S HOSPITAL Free format text: FORMER OWNER: TAICANG SHENGZHOU BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20141204 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 215434 SUZHOU, JIANGSU PROVINCE TO: 200072 PUTUO, SHANGHAI |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20141204 Address after: 200072 No. 301, Yanchang Road, Shanghai Applicant after: Shanghai Tenth People's Hospital Address before: 215434 room 20, building 151, middle Town, pontoon bridge, Taicang, Jiangsu, Suzhou Applicant before: Taicang City Shengzhou Biological Technology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150107 Termination date: 20180802 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |